Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2003
10/16/2003WO2003084480A2 HAUSP-p53 INTERACTION AND USES THEREOF
10/16/2003WO2003084478A2 Antisense modulation of hmgi-c expression
10/16/2003WO2003084476A2 Treatment of lung disorder
10/16/2003WO2003084470A2 Compositions and methods for targeted biological delivery of molecular carriers
10/16/2003WO2003084466A2 FACTORVIIa COMPOSITIONS
10/16/2003WO2003084445A1 Device for mixing and/or injecting cements
10/16/2003WO2003084344A2 Method of improving absorption of vitamin e by a pet animal
10/16/2003WO2003084343A2 Method and dietary composition for improving fat digestibility
10/16/2003WO2003084342A2 Method and dietary composition for improving lipid digestibility
10/16/2003WO2003073104A3 Diagnostic and therapeutic use of ma onconeuronal antigens for neurodegenerative diseases
10/16/2003WO2003068813A3 Group b streptococcus antigen
10/16/2003WO2003065977A9 Modified antigen-presenting cells
10/16/2003WO2003063792A8 Compositions and methods related to tim-3, a th1-specific cell surface molecule
10/16/2003WO2003063778A3 Reducing cholesterol with hydrolyzed whey protein
10/16/2003WO2003062788A3 Method for inhibiting angiogenesis
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003061639A3 Use of glutathione synthesis stimulating compounds in reducing insulin resistance
10/16/2003WO2003057729A3 Mammal prolactin variants
10/16/2003WO2003057650A3 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
10/16/2003WO2003057152A3 Hair follicle growth
10/16/2003WO2003052061A3 Novel human proteins, polynucleotides encoding them and methods of using the same
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003051313A3 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
10/16/2003WO2003047533A3 Composition for treating the surface of the skin
10/16/2003WO2003046560B1 Self-assembly molecules
10/16/2003WO2003046145A3 Materials and methods for making improved liposome compositions
10/16/2003WO2003045335A3 Stem cell screening and transplantation therapy for hiv infection
10/16/2003WO2003045320A3 Somatostatin analog and uses thereof
10/16/2003WO2003040311A3 Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
10/16/2003WO2003039575A3 Use of reelin, gas6, and protein s in the treatment of neural disorders
10/16/2003WO2003039555A3 Agents for treating lesions of the nervous system
10/16/2003WO2003037830A3 Photoactivatable composition and the use of same
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033660A3 9136, a human aldehyde dehydrogenase family member and uses therefor
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003031474A3 Cd137 as a proliferation factor for hematopoietic stem cells
10/16/2003WO2003029426A3 Human and murine cytokine polypeptides
10/16/2003WO2003029413A3 A novel g protein-coupled receptor, gave 10
10/16/2003WO2003028634A3 Method of treatment using ligand-immunogen conjugates
10/16/2003WO2003027639A3 Glucocorticoid receptor nuclear translocation domain
10/16/2003WO2003026492A3 Prevention and treatment of restenosis by local administration of drug
10/16/2003WO2003023034A3 Regulation of human tau-tubulin kinase
10/16/2003WO2003022997A3 Human tissue urokinase type plasminogen activator formulation
10/16/2003WO2003022875A3 Polymorphisms of pd-1
10/16/2003WO2003022218A3 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
10/16/2003WO2003018609A3 Application of peptide conjugates to alzheimer's disease
10/16/2003WO2003016496A3 Zinc finger binding domains for cnn
10/16/2003WO2003016487A3 Mammalian relaxin receptors
10/16/2003WO2003016472A3 Hybrid interferon/interferon tau proteins, compositions and methods of use
10/16/2003WO2003014359A3 A fusion protein
10/16/2003WO2003014160A3 Cd44 variants carrying heparan sulfate chains and uses thereof
10/16/2003WO2003014077A3 Crystal forms and mutants of rank ligand
10/16/2003WO2003012127A3 Assay for identifying inhibitors of hiv rt dimerization
10/16/2003WO2003012034A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/16/2003WO2003011907A3 Receptor, the use thereof, and mouse antibodies
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003011211A3 Peg-modified uricase
10/16/2003WO2003010192A3 An inducer of apoptosis
10/16/2003WO2003008586A3 Engineering oncolytic viruses
10/16/2003WO2003005036A3 Epf receptor assays, compounds and therapeutic compositions
10/16/2003WO2003004520A3 Mycobacterial antigens expressed during latency
10/16/2003WO2003002605A3 Human secretin-like g protein-coupled receptor
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002097043A3 Wnv core protein/capsid interacting protein and uses of the same
10/16/2003WO2002092839A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
10/16/2003WO2002090493A3 Δ4-desaturase genes and uses thereof
10/16/2003WO2002070655A3 Mouse cytokine receptor
10/16/2003WO2002068680A3 Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
10/16/2003WO2002068604A3 Polynucleotide encoding two novel human potassium channel beta-subunits, k+betam4 and k+betam5
10/16/2003WO2002064816A3 Multiple determinants for metabolic phenotypes
10/16/2003WO2002063017A3 Integrin-binding chimeras
10/16/2003WO2002060930A3 Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith
10/16/2003WO2002060473A3 Method for treatment of diabetic retinopathy with naturally occurring insulin-like growth factors (igfs) and igf analogs
10/16/2003WO2002056804A3 Presbyopia treatment by lens alteration
10/16/2003WO2002055101A9 Storage stable powder compositions of interleukin-4 receptor
10/16/2003WO2002044384A3 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003WO2002032954A3 Phosphorylation modifications of apoptin
10/16/2003WO2002029098A3 Genetic factors affecting the outcome of viral infections
10/16/2003WO2002004480A3 Connective tissue growth factor-2
10/16/2003WO2001088148A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/16/2003US20030196212 An isolated nucleic acid sequence encoding a polypeptide specific bind to the receptor; treating infertility, contraception disorders, sexual dysfunction, nervous system disorders, psychiatric disorders, liver disorders
10/16/2003US20030195461 For perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation at wounds from general surgical procedures including oral/dental procedures
10/16/2003US20030195362 For therapy of retroviral infection and in particular an HIV infection
10/16/2003US20030195361 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
10/16/2003US20030195348 CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
10/16/2003US20030195347 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195346 An isolated amino acid sequences are expressed by a cell; for use as human secreted proteins such as human insulin, interferon, Factor VIII, human growth hormones
10/16/2003US20030195345 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195344 A DNA libraries having the vector sequences for coding the membrane receptor proteins, or fusion proteins, for binding the membrane-bound proteins; drug delivery target to specific cell site
10/16/2003US20030195339 A protein is modified with a polyalkylene glycol, granulocyte colony-stimulating factor etherified with a polyoxyethylene glycol; improve protease enzyme resistance; treating patient having reduced granulocytes or thrombocytes
10/16/2003US20030195338 Concatameric immunoadhesion
10/16/2003US20030195337 UL16 binding protein 4
10/16/2003US20030195334 Cell culturing and expressing the protein, chimeric polypeptides, fusion proteins; membrane protein receptor is used to bind the protein drugs thrombolytic agents, interferons, interleukins, erythropoietins
10/16/2003US20030195333 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195331 In situ chlorination, to generate amino acid chlorides, utilizing for solid phase peptide synthesis
10/16/2003US20030195228 Pharmaceutical compositions for hepatitis C viral protease inhibitors
10/16/2003US20030195227 Retroviral protease inhibitors
10/16/2003US20030195198 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
10/16/2003US20030195173 Colchinol derivatives as angiogenesis inhibitors
1 ... 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 ... 3163